C3 and cardiovascular disorder: A BET inhibitor was recently reported to downregulate basal and cytokine-simulated expression of complement components in cultured hepatocytes and humanized mice, and to reduce activated complement C3 and C5 levels in the circulation of cardiovascular disease patients61.